Analysts Set Tourmaline Bio, Inc. (NASDAQ:TRML) Target Price at $45.20
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has been assigned a consensus rating of “Buy” from the six research firms that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in the […]
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has been assigned a consensus rating of “Buy” from the six research firms that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in the […]
